[Health economics studies in dermatology].
Because of reduced resources for health care, provision of modern effective dermatologic care for patients with German public health insurances has become more and more difficult. This survey is designed to aid in the assessment of published health economic studies as well as encourage participation in health economic evaluations. These studies should analyze and optimize the allocation of the available resources. Four main approaches can be used to calculate the incidental expenses; they differ in their methods of evaluation and assessment of health services. They all offer methods to calculate the anticipated costs and consequences. The methods include cost minimization analysis (CMA), cost effectiveness analysis (CEA), cost utility analysis (CUA) or cost benefit analysis (CBA). Many subgroups also exist. Important criteria for the evaluation of health economic trials and hints for the publication of the results are provided on the basis of the recommendations for health economic evaluations.
Rogalski
C
C
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Leipzig. christina.rogalski@medizin.uni-leipzig.de
Simon
J
J
Paasch
U
U
D002986:Clinical Trials as Topic; D003363:Cost Control / Q000191:economics; D003362:Cost-Benefit Analysis; D003879:Dermatologic Agents / Q000191:economics* / Q000627:therapeutic use; D005858:Germany; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D040841:Resource Allocation / Q000191:economics; D012871:Skin Diseases / Q000188:drug therapy / Q000191:economics*
D003879:Dermatologic Agents